Optimal Clinical Trials Ltd | Auckland, New Zealand

Research site

(Unclaimed)

Location

Level 2,97 Grafton Road Grafton, Auckland, Auckland, New Zealand

Site insights

Top conditions

Top treatments

Bimagrumab

KAN-101

Ocrelizumab

Survodutide

mRNA-1345

BI 456906

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)

This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) a...

Active, not recruiting

Primary Progressive Multiple Sclerosis

Relapsing Multiple Sclerosis

Drug: Ocrelizumab SC

Drug: Dexamethasone given orally

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participa...

Enrolling

Celiac Disease

Drug: Cohort 2 in Part A

Drug: Group 4 in Part B and Part C

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Biological: ExPEC9V

Other: Placebo

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting

Respiratory Syncytial Virus

Drug: Placebo

Drug: mRNA-1345

Locations recently updated

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling

Obesity

Drug: Placebo

Drug: survodutide

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and...

Active, not recruiting

Overweight or Obesity

Obese

Drug: Semaglutide

Biological: Bimagrumab

SBD121, a Synbiotic Medical Food for RA Management

The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and...

Enrolling

Rheumatoid Arthritis

Other: SBD121

Other: Placebo